233 related articles for article (PubMed ID: 29220095)
1. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
[TBL] [Abstract][Full Text] [Related]
2. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
[TBL] [Abstract][Full Text] [Related]
3. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
4. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
5. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Robertson S; Acs B; Lippert M; Hartman J
Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
[TBL] [Abstract][Full Text] [Related]
6. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.
Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
Mod Pathol; 2007 Dec; 20(12):1307-15. PubMed ID: 17917671
[TBL] [Abstract][Full Text] [Related]
7. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
8. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
9. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
10. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours.
Focke CM; Decker T; van Diest PJ
Histopathology; 2016 Nov; 69(5):849-861. PubMed ID: 27270560
[TBL] [Abstract][Full Text] [Related]
12. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer.
Robertson S; Stålhammar G; Darai-Ramqvist E; Rantalainen M; Tobin NP; Bergh J; Hartman J
J Clin Pathol; 2018 Sep; 71(9):787-794. PubMed ID: 29588372
[TBL] [Abstract][Full Text] [Related]
15. Digital image analysis outperforms manual biomarker assessment in breast cancer.
Stålhammar G; Fuentes Martinez N; Lippert M; Tobin NP; Mølholm I; Kis L; Rosin G; Rantalainen M; Pedersen L; Bergh J; Grunkin M; Hartman J
Mod Pathol; 2016 Apr; 29(4):318-29. PubMed ID: 26916072
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the methods for measuring the Ki-67 labeling index in adrenocortical carcinoma: manual versus digital image analysis.
Yamazaki Y; Nakamura Y; Shibahara Y; Konosu-Fukaya S; Sato N; Kubota-Nakayama F; Oki Y; Baba S; Midorikawa S; Morimoto R; Satoh F; Sasano H
Hum Pathol; 2016 Jul; 53():41-50. PubMed ID: 26980031
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
19. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
20. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Serna G; Simonetti S; Fasani R; Pagliuca F; Guardia X; Gallego P; Jimenez J; Peg V; Saura C; Eppenberger-Castori S; Ramon Y Cajal S; Terracciano L; Nuciforo P
Breast; 2020 Oct; 53():102-110. PubMed ID: 32707454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]